HAE · Haemonetics Corp
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q1 FY27 earnings call · Aug 6, 2026TL;DR. Haemonetics reported Q1 FY27 revenue of $339 million, up 5.6% reported and 5.9% organic, with adjusted EPS of $1.14 (+3.6%) and raised full-year FY27 reported revenue growth guidance to 5-8% (from 4-7%) and organic growth to 4-7% (from 3-6%), driven by broad-based strength across Apheresis, Blood Management Technologies, and a return to growth in Interventional Technologies.
- + Raised FY27 Apheresis revenue growth guidance to low- to mid-single digits on Q1 outperformance
- + Q1 organic revenue grew 5.9% with broad-based contribution across all three core platforms
- + Blood Management Technologies grew 8% organic with mid-teens disposable growth in hemostasis management
- + Plasma revenue grew 8% organic with North American disposables up mid-20% and EMEA up double-digits
- + Vascular closure returned to low double-digit growth driven by Vascade MVP XL label expansion and improved PFA stability
- + Free cash flow conversion reached 106% of adjusted net income on trailing 12-month basis
- − Adjusted gross margin declined 40 bps YoY to 60.4% and adjusted operating margin declined 70 bps to 23.4%
- − Adjusted tax rate rose to 25.7% from 24.9% due to lower tax benefits on equity compensation
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HAE
this stock
Haemonetics Corp
|
$4.90B | +35.2% | -3.0% | — | 6.3% |
|
ABT
Abbott Laboratories
|
$178.73B | -18.1% | +5.7% | 28.7 | 1.3% |
|
MDT
Medtronic plc
|
$117.85B | -4.1% | +8.4% | 22.7 | 0.9% |
|
SYK
Stryker Corp
|
$105.53B | -21.7% | +11.2% | 28.5 | 2.0% |
|
BSX
Boston Scientific Corp
|
$64.27B | -54.5% | +12.5% | 18.0 | 3.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HAE | +5.6% | +0.2% | +100.6% | +5.2% | +35.3% |
| SPY | -0.3% | -0.1% | +20.1% | -0.7% | +11.7% |
| vs SPY | +5.9% | +0.3% | +80.5% | +5.9% | +23.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.